Drug Insight

Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

Shalender Bhasin, Olga M. Calof, Thomas W. Storer, Martin L. Lee, Norman A. Mazer, Ravi Jasuja, Victor Manuel Montori, Wenqing Gao, James T. Dalton

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.

Original languageEnglish (US)
Pages (from-to)146-159
Number of pages14
JournalNature Clinical Practice Endocrinology and Metabolism
Volume2
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Androgen Receptors
Testosterone
Chronic Disease
Pharmaceutical Preparations
Prostate
Muscle Strength
Therapeutics
Androgens
Transcription Factor 7-Like 2 Protein
Slow-Twitch Muscle Fibers
Fast-Twitch Muscle Fibers
Catenins
Hematocrit
Hypertrophy
Glucocorticoids
Meta-Analysis
Weight Loss
Cell Count
Fats
HIV

Keywords

  • Anabolic therapies
  • Androgens
  • Sarcopenia
  • Selective androgen receptor modulators
  • Testosterone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Drug Insight : Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. / Bhasin, Shalender; Calof, Olga M.; Storer, Thomas W.; Lee, Martin L.; Mazer, Norman A.; Jasuja, Ravi; Montori, Victor Manuel; Gao, Wenqing; Dalton, James T.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 2, No. 3, 03.2006, p. 146-159.

Research output: Contribution to journalArticle

Bhasin, Shalender ; Calof, Olga M. ; Storer, Thomas W. ; Lee, Martin L. ; Mazer, Norman A. ; Jasuja, Ravi ; Montori, Victor Manuel ; Gao, Wenqing ; Dalton, James T. / Drug Insight : Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. In: Nature Clinical Practice Endocrinology and Metabolism. 2006 ; Vol. 2, No. 3. pp. 146-159.
@article{8a0de4fa70274658a7aea57d3b66297b,
title = "Drug Insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging",
abstract = "Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.",
keywords = "Anabolic therapies, Androgens, Sarcopenia, Selective androgen receptor modulators, Testosterone",
author = "Shalender Bhasin and Calof, {Olga M.} and Storer, {Thomas W.} and Lee, {Martin L.} and Mazer, {Norman A.} and Ravi Jasuja and Montori, {Victor Manuel} and Wenqing Gao and Dalton, {James T.}",
year = "2006",
month = "3",
doi = "10.1038/ncpendmet0120",
language = "English (US)",
volume = "2",
pages = "146--159",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Drug Insight

T2 - Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

AU - Bhasin, Shalender

AU - Calof, Olga M.

AU - Storer, Thomas W.

AU - Lee, Martin L.

AU - Mazer, Norman A.

AU - Jasuja, Ravi

AU - Montori, Victor Manuel

AU - Gao, Wenqing

AU - Dalton, James T.

PY - 2006/3

Y1 - 2006/3

N2 - Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.

AB - Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.

KW - Anabolic therapies

KW - Androgens

KW - Sarcopenia

KW - Selective androgen receptor modulators

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=33645274937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645274937&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0120

DO - 10.1038/ncpendmet0120

M3 - Article

VL - 2

SP - 146

EP - 159

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 3

ER -